Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Brokerages

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARMGet Free Report) have earned an average recommendation of “Hold” from the seven brokerages that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $4.94.

CARM has been the topic of a number of research analyst reports. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Evercore ISI reissued an “in-line” rating and set a $0.70 price objective (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. EF Hutton Acquisition Co. I upgraded Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th. BTIG Research cut shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Finally, Baird R W lowered shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th.

Check Out Our Latest Analysis on Carisma Therapeutics

Institutional Trading of Carisma Therapeutics

A number of institutional investors have recently made changes to their positions in CARM. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Carisma Therapeutics during the 2nd quarter valued at $40,000. Wexford Capital LP grew its position in shares of Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after buying an additional 15,000 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after buying an additional 549,290 shares during the last quarter. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Stock Performance

Shares of CARM opened at $0.50 on Friday. Carisma Therapeutics has a 12-month low of $0.38 and a 12-month high of $2.77. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. The company has a market cap of $20.83 million, a PE ratio of -0.32 and a beta of 1.56. The stock has a 50-day moving average price of $0.55 and a 200-day moving average price of $0.86.

Carisma Therapeutics (NASDAQ:CARMGet Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting analysts’ consensus estimates of ($0.31). The business had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. As a group, equities analysts forecast that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.

Carisma Therapeutics Company Profile

(Get Free Report

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.

Read More

Analyst Recommendations for Carisma Therapeutics (NASDAQ:CARM)

Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.